Within tumor tissue, these antibodies prevent the binding between PD-L1 of tumor cells and PD-1 of lymphocytes and thereby restore the anti-cancer immune responses [12], whereby the cytolysis of tumor cells is mainly mediated by CD8+ cyTCs [12]. This evidence concerns the gene PDCD1 and neoplasm.